Page last updated: 2024-08-21

bucrylate and Diabetes Mellitus, Type 1

bucrylate has been researched along with Diabetes Mellitus, Type 1 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Damagé, C; Gouin, E; Hoeltzel, A; Rivereau, AS; Saï, P	1

Other Studies

1 other study(ies) available for bucrylate and Diabetes Mellitus, Type 1

Article	Year
Prophylactic oral administration of metabolically active insulin entrapped in isobutylcyanoacrylate nanocapsules reduces the incidence of diabetes in nonobese diabetic mice. Journal of autoimmunity, 1996, Volume: 9, Issue:6 Topics: Administration, Oral; Adoptive Transfer; Animals; Autoantibodies; Bucrylate; Capsules; Cyclophosphamide; Diabetes Mellitus, Type 1; Female; Humans; Immunosuppression Therapy; Insulin; Intestinal Absorption; Islets of Langerhans; Male; Mice; Mice, Inbred NOD; T-Lymphocytes	1996

Article

Year

Prophylactic oral administration of metabolically active insulin entrapped in isobutylcyanoacrylate nanocapsules reduces the incidence of diabetes in nonobese diabetic mice.

Journal of autoimmunity, 1996, Volume: 9, Issue:6

Topics: Administration, Oral; Adoptive Transfer; Animals; Autoantibodies; Bucrylate; Capsules; Cyclophosphamide; Diabetes Mellitus, Type 1; Female; Humans; Immunosuppression Therapy; Insulin; Intestinal Absorption; Islets of Langerhans; Male; Mice; Mice, Inbred NOD; T-Lymphocytes

1996